Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Niraparib + TSR042 In BRCA Mutated Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04584255
Recruitment Status : Recruiting
First Posted : October 12, 2020
Last Update Posted : January 5, 2021
Sponsor:
Collaborators:
Translational Breast Cancer Research Consortium
Johns Hopkins University
GlaxoSmithKline
Information provided by (Responsible Party):
Erica Mayer, MD, MPH, Dana-Farber Cancer Institute

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 17, 2024
Estimated Study Completion Date : July 17, 2029